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Abstract
The neurotrophic factor ARTEMIN (ARTN) has been reported to possess a role in mammary carcinoma progression and
metastasis. Herein, we report that ARTN modulates endothelial cell behaviour and promotes angiogenesis in ER-mammary
carcinoma (ER-MC). Human microvascular endothelial cells (HMEC-1) do not express ARTN but respond to exogenously
added, and paracrine ARTN secreted by ER-MC cells. ARTN promoted endothelial cell proliferation, migration, invasion and
3D matrigel tube formation. Angiogenic behaviour promoted by ARTN secreted by ER-MC cells was mediated by AKT with
resultant increased TWIST1 and subsequently VEGF-A expression. In a patient cohort of ER-MC, ARTN positively correlated
with VEGF-A expression as measured by Spearman’s rank correlation analysis. In xenograft experiments, ER-MC cells with
forced expression of ARTN produced tumors with increased VEGF-A expression and increased microvessel density (CD31
and CD34) compared to tumors formed by control cells. Functional inhibition of ARTN by siRNA decreased the angiogenic
effects of ER-MC cells. Bevacizumab (a humanized monoclonal anti-VEGF-A antibody) partially inhibited the ARTN mediated
angiogenic effects of ER-MC cells and combined inhibition of ARTN and VEGF-A by the same resulted in further significant
decrease in the angiogenic effects of ER-MC cells. Thus, ARTN stimulates de novo tumor angiogenesis mediated in part by
VEGF-A. ARTN therefore co-ordinately regulates multiple aspects of tumor growth and metastasis.
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Introduction
Tumor growth and metastasis is dependent on de novo
angiogenesis. Clinicopathological correlations between angiogen-
esis and patient survival in mammary carcinoma have been
reported [1]. Microvessel density (MVD) was reported to be
highest with histopathologically aggressive ductal carcinoma-in
situ [1]. High MVD in premalignant lesions has also been
associated with high risk of future mammary carcinoma and high
MVD has been correlated with metastasis and poor survival in
node-negative mammary carcinoma [1]. However, the role of
angiogenesis in mammary carcinoma remains controversial as a
number of studies have indicated lack of therapeutic efficacy of
various anti-angiogenic agents, as tumor re-growth during ongoing
treatment may be observed [2,3]. The reasons for these
discrepancies may depend upon several factors such as inhibition
of vascular endothelial growth factor (VEGF) promoting endothe-
lial vessel normalisation which may decrease delivery of thera-
peutic agents, thereby indirectly promoting tumor growth.
Alternatively, hypoxia due to vascular paucity upon inhibition of
angiogenesis may promote tumor invasion, as evidenced where-
upon anti-angiogenic treatment of glioblastoma (GBM) resulted in
increased intravasation and metastatic dissemination [3]. Such
tumor escape mechanisms may partially explain the lack of
therapeutic efficacy of inhibition of tumor angiogenesis in
mammary carcinoma. In any case, regardless of the controversies
surrounding therapeutic inhibition of angiogenesis in mammary
carcinoma, angiogenesis remains an important component of
tumor growth and metastasis [1].
ARTEMIN (ARTN) is one member of the glial cell line-derived
neurotrophic factor (GDNF) family of ligands [4]. ARTN has
previously been demonstrated to be involved in progression of
various carcinomas [5,6,7] including mammary carcinoma [4].
Increased ARTN expression in mammary carcinoma promotes
metastasis [8], radio-resistance (manuscript submitted), chemo-
resistance [9], endocrine resistance [10] and also enhances CSC
like activity in estrogen receptor negative mammary carcinoma
(ER-MC) (manuscript submitted). Interestingly, another neuro-
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trophic factor, nerve growth factor (NGF), also stimulates tumor
angiogenesis in vivo in mammary carcinoma via the PI3K-AKT
pathway [11]. Similarly, ARTN could potentially modulate not
only tumor growth and metastasis, but also promote angiogenesis
as a contribution to tumor progression leading to poor survival
outcomes in ER-MC [8].
The AKT signalling pathway is pivotal to key cellular functions
in mammary carcinoma including metastasis and angiogenesis
[12]. The expression of various angiogenic factors including
VEGF-A and angiopoietins (ANG), and their receptors, are
regulated by AKT activity in mammary carcinoma. AKT
expression is also correlated with VEGF-A expression and MVD
in mammary carcinoma [12]. Furthermore, AKT activation
controls the tumor microenvironment by promoting endothelial
cell proliferation, survival and migration regulating tumor
angiogenesis through VEGF dependent pathways [13]. Thus,
AKT plays an important role in the tumor angiogenic process.
The basic helix-loop-helix transcription factor TWIST1, also
promotes tumor angiogenesis and metastasis in mammary
carcinoma [14]. Previously we have demonstrated that ARTN
promoted oncogenicity and invasion is mediated by TWIST1 in
ER-MC cells [8]. Promotion of de novo angiogenesis in human
mammary carcinoma by TWIST1 has been reported [15].
Various pro-angiogenic factors including VEGF-A and ANG
and their receptors were demonstrated to be positively regulated
by TWIST1 in murine melanoma cell lines [15]. A recent study
also suggested that TWIST1 positively regulates VEGF-A mRNA
levels in metastatic mammary carcinoma [16]. Furthermore,
TWIST1 mediated angiogenesis in mammary carcinoma in
clinical samples correlates with higher expression of VEGF-A [14].
We report herein that ARTN secreted from mammary
carcinoma cells promotes tumor angiogenesis which is mediated
in part by enhanced VEGF-A expression. Thus, ARTN co-
ordinately regulates angiogenesis and tumor progression of ER-
MC.
Results
Paracrine ARTN Modulates HMEC-1 Proliferation,
Migration, Invasion and Tube Formation
To determine the potential role of ARTN in angiogenesis, we
investigated the effect of ARTEMIN (ARTN) on proliferation and
migration of human microvascular endothelial cells (HMEC-1).
We initially choose two different wild type human mammary
carcinoma cell lines, MCF-7 and MDA-MB-231 with different
endogenous expression levels of ARTN [8] (Figure 1A). Western
blot results confirmed that HMEC-1 cells possessed no detectable
expression of ARTN protein (Figure 1A). MCF-7 cells exhibited
moderate cellular expression; and higher expression and secretion
of ARTN protein was observed in MDA-MB-231 cells. During
tumor angiogenesis, cellular proliferation and invasion of endo-
thelial cells occurs to generate tumor vasculature [13]. We
determined the effects of ARTN secreted by these two mammary
carcinoma cell lines on HMEC-1 monolayer proliferation,
migration, invasion and tube formation as described previously
[17]. The differential expression of the endogenous level of ARTN
protein between MCF-7 and MDA-MB-231 cells significantly
correlated with HMEC-1 monolayer proliferation. HMEC-1 cell
migration, cell invasion, tubule number and tubule length were
also increased significantly by co-culture with MDA-MB-231 cells
as compared with MCF-7 cells (Figure 1B–F).
To determine the involvement of ARTN secreted from
mammary carcinoma cells on endothelial cell angiogenic behav-
iour we transiently depleted endogenous ARTN expression in
MCF-7 and MDA-MB-231 cells by use of siRNA to ARTN [8]
(Figure 1G). Scrambled siRNA was used as control. Depletion of
endogenous ARTN in MCF-7 or MDA-MB-231 cells resulted in
decreased HMEC-1 monolayer proliferation, cell invasion, tubule
number and tubule length in MCF-7 and MDA-MB-231 cells as
compared to co-culture with the respective MCF-7 and MDA-
MB-231 control cell lines (Figure 1H–K). Thus, ARTN secreted
by mammary carcinoma cells may possess an important role in
modulating endothelial cell behaviour.
HMEC-1 Cells Express GFRa Isoforms, RET and Respond
to Exogenous ARTN Stimulation
Previously published work reported that ARTN utilizes GDNF
family receptor a3 (GFRa3) or GFRa1 as a ligand binding
receptor and RET receptor tyrosine kinase as one common
signalling component [18]. Quantitative PCR analysis demon-
strated that HMEC-1 cells express endogenous levels of GFRa1,
GFRa2, GFRa3 and RET mRNA, whereas expression of ARTN
and GFRa4 was not detectable (Figure 2A). HMEC-1 cells can
therefore potentially respond to ARTN.
We next determined whether ARTN exerted direct angiogenic
effects by examination of the effect of different concentrations of
recombinant human ARTN protein (0.1 ng/mL–10 ng/mL) on
HMEC-1 cell function. Exogenously added ARTN significantly
stimulated HMEC-1 monolayer proliferation, cell migration, cell
invasion and tubule formation in HMEC-1 cells (Figure 2B–E).
Thus, ARTN directly modulates endothelial cell behaviour.
ARTN Secreted from ER-MC Cells Promotes Endothelial
Cell Proliferation, Migration, Invasion and Tube
Formation in vitro
A previous report has suggested that ARTN promotes
metastasis of ER-MC cells [8]. Angiogenesis is a crucial
component of metastasis, and pro-angiogenic factors, such as
VEGF-A [1] produced by the tumor cells have been demonstrated
to promote tumor invasiveness, growth and metastasis. Converse-
ly, inhibition of these factors result in decreased tumor growth and
metastasis [1]. To specifically examine the role of ARTN secreted
from ER-MC cells on HMEC-1 cell function, we used two ER-
MC cell lines, MDA-MB-231 or BT549 cells with forced
expression of ARTN as previously described [8]. MDA-MB-231
or BT549 cells stably transfected with empty VEC were used as
control. Expression levels of both cellular and secretory ARTN
proteins are presented in figure S1A–B. The respective cells were
co-cultured with HMEC-1 to determine the effects of ARTN
secreted by MDA-MB-231 or BT549 cells on HMEC-1 mono-
layer proliferation (total cell count), invasion, migration and tube
formation. Forced expression of ARTN in ER-MC cells increased
HMEC-1 monolayer proliferation by 37% and 58% in MDA-MB-
231 or BT549 cells respectively as compared to the matched VEC
control cells (Figure 3A). Next, we determined the effect of ARTN
secreted from ER-MC cells on HMEC-1 cell cycle progression and
apoptotic cell death. Indirect co-culture of HMEC-1 cells with
MDA-MB-231 or BT549 cells with forced expression of ARTN
significantly decreased HMEC-1 apoptotic cell death (22% and
20%) when compared with HMEC-1 cells co-cultured with
respective VEC cells (Figure 3B). Analysis of BrdU incorporation
demonstrated that co-culture of MDA-MB-231 or BT549 cells
with forced expression of ARTN, with HMEC-1 cells, also
increased cell cycle progression (26% and 39%) when compared
with the respective VEC cells co-cultured with HMEC-1 cells
(Figure 3C).
ARTN Promotes Angiogenic Behaviour
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e50098
Figure 1. ARTN secreted from mammary carcinoma cells possesses a functional role in modulating endothelial cell behaviour. (A)
Western blot analysis for ARTN protein expression in HMEC-1, MCF-7 and MDA-MB-231 cells respectively. Soluble whole cell lysates or concentrated
conditioned media were run on an SDS-PAGE and immunoblotted using goat anti-ARTN antibody. b-ACTIN was used as a loading control. (B) HMEC-1
monolayer proliferation. HMEC-1 total cell number after indirect co-culture with either MCF-7 or MDA-MB-231 cells in 2% serum containing media.
Cell growth was measured at the indicated time points. Initial numbers of seeded cell are presented as 100%. As an internal control, HMEC-1 total cell
number assay without co-culture was also performed. (C) HMEC-1 cell migration after 24 h indirect co-culture with either MCF-7 or MDA-MB-231 cells
in serum free conditions. Numbers of migrated HMEC-1 cells without co-culture are presented as 100%. (D) HMEC-1 cell invasion assay after 24 h
indirect co-culture with either MCF-7 or MDA-MB-231 cells in serum free conditions. Migratory or invasive cell numbers was calculated as (number of
invaded cells through the inserts/total number of cells seeded)6100. Numbers of invaded HMEC-1 cells without co-culture are presented as 100%.
(E) and (F) HMEC-1 cells in vitro tube formation in matrigel after 12 h indirect co-culture with either MCF-7 or MDA-MB-231 cells in serum free
conditions. HMEC-1 tubule number (E) and tubule length (F) was assessed after 12 h. Tubule number was calculated as (number of cells with tubule/
total number of cells counted)6 100, whereas tubule length was calculated as an arbitrary units using ImageJ softwareH. As an internal control,
HMEC-1 tubule number and tubule length was also assessed without co-culture. (G) Western blot analyses for ARTN in MCF-7 and MDA-MB-231
cells6 siRNA to ARTN. Scrambled RNA was used as siCONT. b-ACTIN was used as loading control for cell lysates. The sizes of detected protein bands
in kiloDalton (kDa) are shown on the right. (H) HMEC-1 monolayer proliferation. HMEC-1 cell numbers after indirect co-culture with either MCF-7 or
MDA-MB-231 cells in 2% serum containing media 6 siRNA of ARTN. Scrambled RNA was use as control. Cells growth was measured at the indicated
time points. Initial numbers of seeded cell are presented as 100%. (I) HMEC-1 cell invasion assay after 24 h indirect co-culture with either MCF-7 or
MDA-MB-231 cells in serum free conditions 6 siRNA of ARTN. HMEC-1 tubule number (J) and tubule length (K) was assessed after indirect co-culture
with either MCF-7 or MDA-MB-231 cells 6 siRNA of ARTN. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0050098.g001
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To determine the effects of ARTN secreted from ER-MC cells
on the migratory and invasive behaviour of endothelial cells, we
performed cell migration and cell invasion assays on HMEC-1
cells co-cultured with either MDA-MB-231 or BT549 VEC or
ARTN cells respectively. Indirect co-culture of MDA-MB-231 or
BT549 cells with forced expression of ARTN significantly
increased HMEC-1 cell migration (39% and 55%) and cell
invasion (32% and 53%) over a 24 hr period when compared with
respective VEC cells (Figure 3D and E).
Endothelial cells organize when cultured in matrigel and form
three dimensional capillary like tubule structures with multiple cell
to cell contacts, thus mimicking angiogenesis in vitro [17]. To
determine the effects of ARTN on endothelial cell tube formation
in vitro, we performed a tube formation assay with HMEC-1 cells
co-cultured with either MDA-MB-231 or BT549 VEC or ARTN
cells respectively. Forced expression of ARTN in MDA-MB-231
or BT549 cells significantly increased the tubule number (121%
and 136%) and tubule length (91% and 97%) generated by
HMEC-1 cells compared with HMEC-1 cells co-cultured with
respective control MDA-MB-231 or BT549 cells (Figure 3F–H).
Depletion of ARTN in ER-MC Cells Inhibited Endothelial
Cell Proliferation, Migration, Invasion and Tube
Formation in vitro
We next examined the effects of depletion of endogenous
ARTN from ER-MC cells on angiogenic behaviour of HMEC-1
cells. We utilized MDA-MB-231-siARTN and BT549-siARTN
cell lines stably transfected with siRNA to ARTN as previously
described [8]. Scrambled control siRNA was used to establish the
respective siCONT cells [8]. Expression levels of both cellular and
secretory ARTN proteins in these respective groups are presented
in figure S1A–B. Respective siCONT and siARTN cells were co-
cultured with HMEC-1 to determine the effects of depletion of
ARTN on monolayer proliferation (total cell count), invasion,
migration and tube formation. Depletion of ARTN expression in
MDA-MB-231 or BT549 cells decreased HMEC-1 monolayer
proliferation by 23% and 16% as compared to respective siCONT
control cells (Figure 4A). Next, we examined the effect of depletion
of ARTN from ER-MC cells on HMEC-1 cell cycle progression
and apoptotic cell death. Indirect co-culture of HMEC-1 cells with
MDA-MB-231 or BT549 cells with depleted expression of ARTN
significantly increased HMEC-1 apoptotic cell death (29% and
22%) when compared with HMEC-1 cells co-cultured with
respective siCONT cells (Figure 4B). Analysis of BrdU incorpo-
ration demonstrated that co-culture of HMEC-1 cells with MDA-
MB-231 or BT549 cells with depleted expression of ARTN
exhibited decreased HMEC-1 cell cycle progression (17% and
26%) when compared with respective siCONT cells co-cultured
with HMEC-1 cells (Figure 4C).
Indirect co-culture of MDA-MB-231 or BT549 cells with
depletion of ARTN significantly decreased HMEC-1 cell migra-
tion (28% and 36%) and cell invasion (23% and 31%) over a 24 hr
period when compared with respective siCONT cells (Figure 4D
and E). Depletion of ARTN in ER-MC cells also significantly
decreased the tubule number (40% and 33%) and tubule length
(43% and 35%) generated by HMEC-1 cells compared with
Figure 2. Exogenous ARTN modulates HMEC-1 cell behaviour. (A) The expression of ARTN, GRFa1-4 and RET in HMEC-1 cells determined by
quantitative real time PCR. Cellular behaviour of HMEC-1 cells, including, (B) Monolayer proliferation. (C) Cell migration. (D) Cell invasion. (E) in vitro
tubule formation on matrigel were assessed in the presence of different concentration of recombinant ARTN. Recombinant ARTN was added at the
indicated concentrations every two days. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0050098.g002
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HMEC-1 cells co-cultured with the respective MDA-MB-231 or
BT549 siCONT cells (Figure 4F–H).
To further verify our previous data we utilized an alternate
siRNA to ARTN (siARTN A) [10] to selectively deplete ARTN
expression in BT549 cells. Scrambled siRNA was used as control
Figure 3. Forced expression of ARTN in ER-MC cells increases the angiogenic potential of HMEC-1 cells. (A) HMEC-1 monolayer
proliferation. HMEC-1 total cell number after indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in 2% serum
containing media. Empty VEC was used as control. Cell growth was measured at the indicated time points. (B) HMEC-1 apoptotic cell death after 24 h
indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in serum free conditions. (C) HMEC-1 cell cycle progression after
24 h indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in serum free conditions. (D) HMEC-1 cell migration after
24 h indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in serum free conditions. (E) HMEC-1 cell invasion assay after
24 h indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in serum free conditions. (F) and (G) HMEC-1 cells in vitro
tube formation on matrigel after 12 h indirect co-culture with MDA-MB-231 or BT549 cells with forced expression of ARTN in serum free conditions.
HMEC-1 tubule number (F) and tubule length (G) was assessed after 12 h. Tubule number was calculated as (number of cells with tubule/total
number of cells counted) 6 100, whereas tubule length was calculated as an arbitrary units using ImageJ softwareH. (H) Representative light
microscopy images of tube formation. Bar 200 mm.*, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0050098.g003
ARTN Promotes Angiogenic Behaviour
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e50098
[8]. Depletion of ARTN by siARTN-A in BT549-VEC cells was
confirmed by western blot (Figure S2A). As previously observed,
siRNA mediated depletion of ARTN with the alternate siRNA to
ARTN also resulted in decreased HMEC-1 mediated monolayer
proliferation (20%), cell invasion (30%) and 3D matrigel tubule
Figure 4. Depleted expression of ARTN in ER-MC cells decreases the angiogenic potential of HMEC-1 cells. (A) HMEC-1 monolayer
proliferation. HMEC-1 total cell numbers after indirect co-culture with MDA-MB-231 or BT549 cells with depleted expression of ARTN in 2% serum
media. Scrambled siRNA was used as control (siCONT). Cell growth was measured at the indicated time points. (B) HMEC-1 apoptotic cell death after
24 h indirect co-culture with MDA-MB-231 or BT549 cells with depleted expression of ARTN in serum free conditions. (C) HMEC-1 cell cycle
progression after 24 h indirect co-culture with MDA-MB-231 or BT549 cells with depleted expression of ARTN in serum free conditions. (D) HMEC-1
cell migration after 24 h indirect co-culture with MDA-MB-231 or BT549 cells with depleted expression of ARTN. (E) HMEC-1 cell invasion assay after
24 h indirect co-culture with MDA-MB-231 or BT549 cells with depletion expression of ARTN. (F) and (G) HMEC-1 cells in vitro tube formation on
matrigel after 12 h indirect co-culture with MDA-MB-231 or BT549 cells with depleted expression of ARTN. HMEC-1 tubule number (F) and tubule
length (G) was assessed after 12 h. Tubule number was calculated as (number of cells with tubule/total number of cells counted)6 100, whereas
tubule length was calculated as an arbitrary unit using ImageJ softwareH. (H) Representative light microscopy images of tube formation. Bar
200 mm.*, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0050098.g004
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formation (25%) compared to BT549 siCONT cells (Figure S2B–
E).
ARTN Activation of TWIST1 in ER-MC is Upstream of
VEGF-mediated Angiogenic Behaviour of HMEC-1 Cells
We have previously reported that AKT/TWIST1 mediates
ARTN stimulated invasion of ER-MC cells [8]. AKT and
TWIST1 have also been implicated to possess a functional role
in de novo angiogenesis in mammary carcinoma [14,19]. PI3K/
AKT signalling is an important pathway regulating various pro-
angiogenic factors, such as HIF1a and VEGF-A [20]. To
determine if AKT mediates ARTN enhancement of the angio-
genic potential of ER-MC cells, we first employed siRNA to
AKT1 to deplete AKT and therefore inhibit AKT activity in
MDA-MB-231 cells. Treatment of MDA-MB-231-VEC cells with
siAKT decreased the basal levels of pAKT and total AKT. ARTN
stimulated activation of AKT was also decreased by siAKT
(Figure 5A, upper panel). siAKT also decreased the basal level of
TWIST1 expression in MDA-MB-231-VEC cells and also
significantly inhibited ARTN stimulated TWIST1 expression in
MDA-MB-231-ARTN cells, as previously demonstrated using
AKT inhibitor IV [8]. Depletion of AKT in MDA-MB-231 cells
abrogated the stimulatory effects of ER-MC cells on HMEC-1
tube formation (Figure 5B). Furthermore, treatment with AKT
inhibitor IV in MDA-MB-231 cells with forced expression of
ARTN [8] also resulted in decreased HMEC-1 tube formation
(Figure S3).
We have previously demonstrated [8] that AKT activation by
ARTN in MDA-MB-231 cells resulted in increased expression of
TWIST1. Forced expression of TWIST1 in ER-MC cells has been
reported to produce increased tumor angiogenesis resulting in an
aggressive carcinoma phenotype [14]. To determine whether
TWIST1 mediates ARTN stimulation of the angiogenic potential
of ER-MC cells, we employed siRNA to TWIST1 [8] to selectively
deplete TWIST1 expression in MDA-MB-231 cells. siTWIST1
selectively reduced TWIST1 protein expression in MDA-MB-231-
VEC cells as evident in Figure 5A, lower panel. b-ACTIN was
used an internal control. Depletion of TWIST1 abrogated the
stimulatory effects of ARTN from both MDA-MB-231-VEC and
cells with forced expression of ARTN on HMEC-1 tube formation
(Figure 5C).
It has been previously reported that VEGF-A mediates at least
some of the angiogenic effects of mammary carcinoma cells [17].
q-PCR gene expression data demonstrated that forced expression
of ARTN in MDA-MB-231 cells significantly increased VEGF-A
mRNA expression as compared to control cells (Figure 5D).
Similarly, forced expression of ARTN in MDA-MB-231 cells
increased VEGF-A protein expression compared to control cells
(Figure 5E upper panel). Furthermore, we demonstrated that
exogenously added ARTN increased VEGF-A expression in
HMEC-1 cells. Higher concentrations of exogenously added
ARTN resulted in increased VEGF-A expression in HMEC-1 cells
(Figure 5E lower panel).
TWIST1 signalling has been reported to promote VEGF-A
expression in mammary carcinoma cells [14] and we have
previously demonstrated that ARTN increased TWIST1 expres-
sion to modulate ARTN stimulated oncogenicity [8]. We therefore
next determined if depletion of TWIST1 by siRNA would
abrogate ARTN dependent VEGF-A expression in MDA-MB-
231 cells with forced expression of ARTN. As observed [8],
western blot analysis demonstrated that depletion of TWIST1 in
MDA-MB-231-VEC cells reduced the basal level of VEGF-A
expression compared to MDA-MB-231-VEC cells with siCONT.
Further, depletion of TWIST1 by siRNA also specifically
abrogated the enhanced VEGF-A expression observed in MDA-
MB-231-ARTN cells as compared to MDA-MB-231-ARTN cells
with siCONT (Figure 5F).
We next analysed the depletion of VEGF-A expression in ER-
MC cells on the ability of ARTN to stimulate tube formation by
HMEC-1 cells. We employed siRNA to VEGF-A to selectively
reduce VEGF-A expression in MDA-MB-231 cells. siVEGF-A
selectively reduced VEGF-A protein expression in MDA-MB-231-
VEC and MDA-MB-231-ARTN cells as observed in Figure 5G.
Depletion of VEGF-A in MDA-MB-231-VEC cells reduced tube
formation by HMEC-1 cells in co-culture compared to co-culture
with MDA-MB-231-VEC cells transfected with siCONT
(Figure 5H). Depletion of VEGF-A in MDA-MB-231-ARTN cells
also partially abrogated the stimulatory effects of ARTN on
HMEC-1 tubule number and tubule length (Figure 5H–J). We also
analysed the functional effects on HMEC-1 cells of VEGF-A
antagonism in MDA-MB-231 cells with forced expression of
ARTN. Functional antagonism of VEGF-A was achieved using
the inhibitory humanized monoclonal antibody bevacizumab [21].
Functional antagonism of VEGF-A with bevacizumab partially
abrogated ARTN-mediated stimulation of HMEC-1 tube forma-
tion when co-cultured with MDA-MB-231 cells with forced
expression of ARTN (Figure S4A–B). Bevacizumab also signifi-
cantly reduced HMEC-1 tube formation when co-cultured with
MDA-MB-231-VEC cells as expected [17] (Figure S4A–B).
We lastly investigated the effects of combined functional
antagonism of ARTN and VEGF-A from ER-MC cells (MDA-
MB-231) on the ability of HMEC-1 cells to form tubules.
Treatment of MDA-MB-231-WT cells with bevacizumab alone
significantly decreased tubule number (Figure S4C). Combined
depletion of ARTN with siRNA to ARTN and treatment with
bevacizumab resulted in a further reduction in tubule number
(Figure S4C). ARTN therefore possesses both VEGF-A dependent
and VEGF-A independent effects on endothelial cell behaviour.
Correlation between ARTN and VEGF-A Expression in ER-
MC
We next determined a potential correlation between VEGF-A
expression and ARTN expression in a cohort of patients with ER-
MC by IHC analysis. IHC analysis showed that ARTN and
VEGF-A protein were highly expressed in ER-MC (Figure S5). To
assess any possible correlation between ARTN and VEGF
expression, we stratified the expression level of each protein into
two categories (low and high expression). Of those tumors with low
expression of ARTN, only 17.1% exhibited high VEGF expression
whereas 56.6% of tumors with high ARTN expression also
exhibited high VEGF expression. To further confirm the
correlation of expression between ARTN and VEGF, we
compared the relationship by Spearman’s rank correlation co-
efficient and found a significant positive value (Spearman
correlation: rs = 0.301, P=0.008) (Table 1). Thus, expression of
ARTN in ER-MC partially correlates with VEGF-A expression.
ARTN Secreted from ER-MC Cells Promotes Tumor
Angiogenesis in vivo
To determine the potential in vivo role of ARTN secreted from
ER-MC cells in tumor angiogenesis, we injected MDA-MB-231-
ARTN cells into the mammary fat pad of immunodeficient nude
mice. After 4 weeks, MDA-MB-231-ARTN tumors grew signif-
icantly larger than MDA-MB-231-VEC tumors as described [8].
Previous reports indicate that higher expression of VEGF-A
correlates with increased tumor vasculature in patients with
invasive mammary carcinoma [22]. We therefore determined the
ARTN Promotes Angiogenic Behaviour
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Figure 5. VEGF-A is downstream of ARTN stimulated TWIST1 activation in ER-MC. (A) Western blot analyses for phospho AKT Ser 473
(pAKT), total AKT and TWIST1 expression in MDA-MB-231 cells with forced expression of ARTN6 siRNA to AKT (upper panel) or TWIST1 expression in
MDA-MB-231 cells with forced expression of ARTN 6siRNA to TWIST1 (lower panel). Scrambled RNA was used as siCONT. b-ACTIN was used as
ARTN Promotes Angiogenic Behaviour
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expression of VEGF-A by IHC in xenograft tumors derived from
MDA-MB-231-VEC and MDA-MB-231-ARTN cells. VEGF-A
protein expression was higher in xenografts derived from MDA-
MB-231-ARTN cells as compared to xenografts derived from
control VEC cells (Figure 6A).
To examine microvessel density (MVD), CD31 and CD34
protein expression was also determined by immunohistochemistry.
We observed an increased area of CD31 and CD34-labelled cells
in xenografts derived from MDA-MB-231-ARTN as compared to
xenograft derived from MDA-MB-231-VEC tumors, indicating
significantly increased tumor microvessel density (Figure 6B). Thus
expression of ARTN in ER-MC cells promotes tumor angiogen-
esis in vivo.
Discussion
Tumor angiogenesis is proposed to be multistep process that
permits tumor cells to access the circulation and metastasize to
distant organ sites [23]. Undoubtedly, VEGF-A is an important
mediator of angiogenesis in mammary carcinoma. VEGF-A is
reported to be predominantly expressed in early stage mammary
carcinoma [24]. However, during malignant progression several
other known molecular mediators may also interplay to promote
angiogenesis [25,26]. Therefore targeting VEGF-A alone would
not be sufficient to provide maximal potential therapeutic benefits.
Herein we have demonstrated that ARTN directly regulates
endothelial cell function. Furthermore, we have demonstrated that
ARTN secreted by ER-MC cells also regulates endothelial cell
function, at least in part by increasing the expression of VEGF-A
from mammary carcinoma cells. ARTN may also, in addition to
VEGF-A, regulate other factors promoting angiogenesis. Indeed,
gene expression studies on MCF-7 cells with forced expression of
ARTN [4] demonstrated that ARTN regulates several pro-
angiogenic factors, including MMP1 [27] and PLAU [28]. We
have also observed increased IL-8 expression in BT549 cells with
forced expression of ARTN (unpublished observations). IL-8 is a
well described promoter of tumor angiogenesis [29]. Thus, apart
from direct actions on endothelial cells, ARTN also co-ordinately
regulates a pro-angiogenic programme of gene expression from
mammary carcinoma cells. Recently, cancer stem cells (CSCs)
have been reported to secrete angiogenic factors such as VEGF-A
to provide vasculature to support CSC renewal [30]. In this
regard, it is interesting that we have reported that ARTN
promotes CSC-like behaviour in ER-MC cell lines (manuscript
submitted). Thus, ARTN modulation of endothelial cell behaviour
promoting de novo angiogenesis may occur as part of a co-ordinated
tumor growth process involving cells with CSC-like behaviour.
Indeed, similar to ARTN, VEGF-A has been reported to promote
cancer cell proliferation and metastasis [31], tumor growth [32],
CSC-like behaviour [33], and angiogenesis [34]. VEGF-A is
apparently one mediator of the co-ordinated oncogenic properties
of ARTN [4,8] which now includes angiogenesis.
We report herein that ARTN regulation of VEGF-A is
mediated by AKT-TWIST1. Concordant with our results herein
and previously [8], higher expression of AKT, TWIST1 and
VEGF-A has been reported in metastatic mammary carcinoma
[12,14,16]. ARTN has also been reported to utilize the AKT-
TWIST1 pathway for stimulation of CSC-like behaviour (manu-
script submitted). Given that VEGF-A also stimulates CSC-like
behaviour it is plausible that VEGF-A partially mediates the CSC-
like promoting behaviours of ARTN. Interestingly, ARTN also
promotes the expression of other secreted proteins, such as TFF3
[10] which also promotes the oncogenic behaviour of mammary
carcinoma cells [35] and possesses angiogenic activity [36]. ARTN
may therefore stimulate a co-ordinated programme of gene
expression promoting oncogenicity of mammary carcinoma and
progression of the clinical disease.
ARTN, like other GFLs has been reported to utilize GFRa
mediated RET signalling [18]. We have demonstrated herein that
ARTN regulates VEGF-A in ER-MC cells. Interestingly, MDA-
MB-231 cells do not express RET [37], yet ARTN activates the
AKT pathway in MDA-MB-231 cells [8]. It is relevant that GFLs,
including ARTN, bind to and/or activate multiple receptors/
signalling pathways [18]. Indeed, ARTN has recently been
demonstrated to bind and activate syndecan-3, leading to
activation of Src kinase, in addition to binding to GFRa3 and
GFRa1 [38]. It is possible that different upstream signalling
pathways converge to activate AKT leading to increased VEGF-A
expression via TWIST1 and ARTN may therefore activate the
loading control for cell lysates. The sizes of detected protein bands in kiloDalton (kDa) are shown on the right. Here ‘‘V’’ used as MDA-MB-231-VEC
cells and ‘‘A’’ used as MDA-MB-231-ARTN cells respectively. (B) HMEC-1 tubule number was assessed after 12 h indirect co-culture with forced
expression of ARTN cells of MDA-MB-2316 siAKT. Tubule number was calculated as (number of cells with tubule/total number of cells counted)6
100. (C) HMEC-1 tubule number was assessed after 12 h indirect co-culture with forced expression of ARTN cells of MDA-MB-2316 TWIST1 siRNA.
Tubule number was calculated as (number of cells with tubule/total number of cells counted)6100. (D) VEGF-A mRNA levels were determined by q-
PCR in MDA-MB-231 cells with forced expression of ARTN and expressed as the relative expression compared to the MDA-MB-231-VEC cells. (E)
Western blot analysis of VEGF-A in MDA-MB-231-VEC and -ARTN cells (upper panel) and for VEGF-A in HMEC-1 cells were assessed in the presence of
different concentration of recombinant ARTN (lower panel). b-ACTIN was used as loading control for cell lysates. The sizes of detected protein bands
in kDa are shown on the right. Here ‘‘V’’ used as MDA-MB-231-VEC cells and ‘‘A’’ used as MDA-MB-231-ARTN cells respectively. (F) Western blot
analyses for VEGF-A in MDA-MB-231-VEC and -ARTN cells6 siRNA to TWIST1. Universal negative control was used as an internal control. b-ACTIN was
used as loading control for cell lysates. The sizes of detected protein bands in kDa are shown on the right. (G) Western blot analyses for VEGF-A
expression in MDA-MB-231 cells 6 siRNA to VEGF-A. Scrambled RNA was used as siCONT. b-ACTIN was used as loading control for cell lysates. The
sizes of detected protein bands in kiloDalton (kDa) are shown on the right. Here ‘‘V’’ used as MDA-MB-231-VEC cells and ‘‘A’’ used as MDA-MB-231-
ARTN cells respectively. (H) HMEC-1 tubule number and (I) tubule length was assessed after 12 h indirect co-culture with forced expression of ARTN
cells of MDA-MB-2316 siRNA to VEGF-A. Scrambled RNA was used as siCONT. Tubule number was calculated as (number of cells with tubule/total
number of cells counted) 6 100, whereas tubule length was calculated as an arbitrary units using ImageJ softwareH. (J) Representative light
microscopy images of tube formation with MDA-MB-231 cells with forced expression of ARTN or control VEC 6 siVEGF-A. Bar 200 mm. **, p,0.01.
doi:10.1371/journal.pone.0050098.g005
Table 1. Correlation between ARTN and VEGF-A expression
in ER negative mammary carcinoma.
ARTN expression
Low High
VEGF expression Low 11 (14.5%) 9 (11.8%)
High 13 (17.1%) 43 (56.6%)
Spearman correlation: P =0.008 rs = 0.301.
Footnotes:
Expression parameters are described in details in the Materials and methods
section.
doi:10.1371/journal.pone.0050098.t001
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Figure 6. Forced expression of ARTN in ER-MC cells stimulates tumor angiogenesis. (A) Immunohistochemical analysis of VEGF-A, CD31
and CD34 protein levels in xenograft tumors formed by MDA-MB-231 cells with forced expression of ARTN and control VEC. (B) Microvessel density
(MVD) was assessed by quantifying percentage of area of CD31 or CD34 labelled cells in xenograft formed by either MDA-MB-231 cells with forced
expression of ARTN or control VEC.
doi:10.1371/journal.pone.0050098.g006
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AKT-TWIST1-VEGF-A axis independent of RET. The precise
upstream signalling pathways utilized by ARTN to regulate
VEGF-A remain to be determined. ARTN may also utilize other
signalling pathways to regulate distinct alternate pro-angiogenic
genes.
In summary, we have demonstrated herein that ARTN
promotes de novo tumor angiogenesis mediated in part by increased
VEGF-A expression. ARTN therefore co-ordinately regulates
processes promoting tumor growth and metastasis. Such co-
ordinate regulation of tumor growth and metastasis warrants
consideration of the use of therapeutic strategies inhibitory to
ARTN activity in ER-MC.
Materials and Methods
Cell Culture
Cell lines used in this study were obtained from the ATCC
(American Type Culture Collection) and cultured as recom-
mended. Generation of MDA-MB-231 or BT549 cells with forced
expression or depleted expression of ARTN have been previously
described [8]. Human microvascular endothelial cells (HMEC-1)
were cultured as described previously [17].
Reagents
Recombinant human ARTN was purchased from Peprotech
inc, NJ, USA. AKT Inhibitor IV and siRNA to TWIST1 were
purchased as previously described [8]. Stealth siRNAs to AKT,
TWIST1 and VEGF-A were purchased from Invitrogen Inc, CA.
Bevacizumab was purchased from Roche Diagnostics, NZ. siRNA
to ARTN (siARTN-A) were as previously described [10].
Polymerase Chain Reaction
Quantitative real time PCR primers were used as described
earlier [6]. q-PCR was performed as described previously [8] and
VEGF-A primers used were identical to those in a previous report
[17].
Immunoblotting
Western blot analysis was performed as described earlier [8]
using the following antibodies: goat anti-ARTN polyclonal
antibody (R&D Systems, Minneapolis, MN) mouse anti-b-ACTIN
monoclonal antibody (Sigma, St Louis, MO) and mouse anti-
VEGF-A monoclonal antibody (SantaCruz, CA). pAKT(Ser473),
total AKT and TWIST1 antibody were used as previously
mentioned [8].
Cell Function Assays
Indirect co-culture of mammary carcinoma cells with HMEC-1
cells for determination of monolayer proliferation assay, cell
migration, cell invasion, tube formation assays were performed as
previously described [17]. Monolayer proliferation assay, cell
migration and cell invasion assay were performed as described
previously [8] and tubule formation assay was performed as stated
earlier [17]. Apoptosis assay was performed as described
previously [9] using Annexin-V-FLUOS staining kit (Roche,
Mannheim, Germany) and BrdU assays were performed as
described previously [17].
Tumor Xenograft in Nude Mice
All animal work was done in accordance with a protocol
approved by the institutional animal care and use committee.
Tumor growth was achieved as mentioned earlier [8]. Immuno-
histochemical (IHC) analysis of paraffin-embedded specimens was
performed as described previously [4]. In short, 6 mm tissue
sections were cut, sections were deparaffinised in xylene,
rehydrated in a graded series of ethanol solutions, and heated in
a microwave oven in 0.01 M sodium citrate buffer (pH 6.0) for 10
minutes for antigen retrieval. All of the antibodies including anti-
VEGF (Cat No.MAB-0243, 1:50), anti-CD31 (Cat No.MAB-0031,
1:50) and anti-CD34 (Cat No.MAB-0034, 1:50) were bought from
Maixin Biotechnology Development Co.Ltd (Fuzhou, China).
Histopathological Analysis
Tissue samples were collected from 76 female breast cancer
patients with ER-MC from the First Affiliated Hospital of Anhui
Medical University (Hefei, P. R. China) presenting between 2001
and 2002. Institutional ethics committee approval for the project
was obtained before commencement of the study and was in
compliance with the Helsinki Declaration. Immunohistochemical
analysis of paraffin-embedded specimens was performed as
described previously [4].
Statistics
All numerical data are expressed as mean6S.E.M. and
statistical significance was assessed by Student’s t-test (P,0.05
was considered as significant) using Microsoft Excel XP unless
otherwise indicated (x2 test).
Supporting Information
Figure S1 Western blot analysis for ARTN in (A) wild type cells
of MDA-MB-231 and BT549 or (B) in MDA-MB-231 and BT549
cells with forced expression or depletion of ARTN. b-ACTIN was
used as loading control for cell lysates. The sizes of detected
protein bands in kiloDalton (kDa) are shown on the right. Soluble
whole cellular extracts or concentrated conditioned media were
run on an SDS-PAGE.
(TIF)
Figure S2 Depleted expression of ARTN decreases angiogenic
potential of HMEC-1 cells. (A) Western blot analyses for ARTN in
BT549 cells with siRNA mediated depletion of ARTN. b-ACTIN
was used as loading control for cell lysates. The sizes of detected
protein bands in kiloDalton (kDa) are shown on the right. (B)
HMEC-1 monolayer proliferation. HMEC-1 total cell numbers
after indirect co-culture with BT549 cells with depleted expression
of ARTN in 2% serum media. Cell growth was measured at the
indicated time points. Scrambled siRNA was used as control
(siCONT). (C) HMEC-1 cell invasion assay after 24 h indirect co-
culture with BT549 cells with depletion expression of ARTN. (D)
and (E) HMEC-1 cells in vitro tube formation on matrigel after
12 h indirect co-culture with BT549 cells with depleted expression
of ARTN. HMEC-1 tube formation was assessed after 12 h.
Tubule number was calculated as (number of cells with tubule/
total number of cells counted)6 100. Bar 200 mm.*, p,0.05; **,
p,0.01.
(TIF)
Figure S3 HMEC-1 tubule number was assessed after 12 h
indirect co-culture with forced expression of ARTN cells of MDA-
MB-2316 AKT inhibitor IV as previously described [8]. Tubule
number was calculated as (number of cells with tubule/total
number of cells counted)6 100. **, p,0.01.
(TIF)
Figure S4 VEGF-A is downstream of ARTN stimulated
angiogenesis in ER-MC. (A) HMEC-1 tubule number and (B)
tubule length was assessed after 12 h indirect co-culture with
forced expression of ARTN cells of MDA-MB-2316 bevacizu-
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mab. Human IgG was used as control. Tubule number was
calculated as (number of cells with tubule/total number of cells
counted) 6 100, whereas tubule length was calculated as an
arbitrary units using ImageJ softwareH. (C) HMEC-1 tubule
number was assessed after 12 h indirect co-culture with MDA-
MB-231-wild type (MDA-MB-231-WT) in the presence of either
bevacizumab (0.5 mg/mL) alone or with siRNA to ARTN.
Control cells were treated with human IgG, siCONT of ARTN.
Tubule number was calculated as (number of cells with tubule/
total number of cells counted)6 100. *, p,0.05; **, p,0.01.
(TIF)
Figure S5 Immunohistochemistry (IHC) images of ARTN and
VEGF-A expression in ER-MC. (A) ARTN and VEGF-A
expression was detected by IHC analysis in ER-MC samples.
Both ARTN and VEGF-A are predominantly localized to
cytoplasm of carcinoma cells. X200 magnifications.
(TIF)
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